Etoposide

製品コードS1225 別名:VP-16, VP-16213

Etoposide化学構造

分子量(MW):588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 46480.00
JPY 114540.00
JPY 164340.00

カスタマーフィードバック(5)

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
ターゲット
Topo II [2]
(Cell-free assay)
体外試験

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NUHJdIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMUNihKnDueLCiUCuNFEh|ryP MlS1NlU6PjB{OEK=
KellyCis83 M1HRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{GzcGlEPTB;MD6xOwKBkcLz4pEJNE4xOiEQvF2= MX2yOVk3ODJ6Mh?=
SK-N-AS M{K2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMkVihKnDueLCiUCuNFMh|ryP NEewS3EzPTl4MEK4Ni=>
SK-N-ASCis24 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwNUhihKnDueLCiUCuNVEh|ryP NXrIWpVUOjV7NkCyPFI>
U87 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLkNE02OCEQvF2= MlTGOFghcA>? Mnez[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfobYNpKGOjbjDi[UBmdmijbnPl[EBjgSC|aXzpZolvcW5? MVyyOVc2ODJ5Mx?=
HCT116 NUHTZmVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfhRYRHOC53LUKuOUDPxE1? NXzEd4ZpPDkEoHlCpC=> MlmzTWM2OD1zLkezxsDDucLiMD6yNeKh|ryP NFfnU2QzPTd2Nke2Ny=>
HT-29 NUPpT|FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXRNlN2OC53LUKuOUDPxE1? MnjsOFjDqGkEoB?= Mn7MTWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? MUWyOVc1Pjd4Mx?=
Caco2 M2K3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6wMlUuOi53IN88US=> MUG0POKhcMLi M2rOVGlEPTB;Nz6yOuKhyrIEoEGuOljDqM7:TR?= MUGyOVc1Pjd4Mx?=
COLO 205 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\iZlAvPS1{LkWg{txO M{f3SVQ5yqCqwrC= NGLLSVBKSzVyPUGuOlHDqMLzwrCwMlAzyqEQvF2= NYTmcm9tOjV5NE[3OlM>
SW480 NXv3fmhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSwMlUuOi53IN88US=> MmCwOFjDqGkEoB?= NYHxfGJSUUN3ME20MlkzyqEEsdMgNE4{O8LizszN M1;kSFI2PzR4N{[z
HEK293T NHTpcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILtSXkyNTVizszN MYG0POKhcMLi MWjJR|UxRTJwNENCpOKyyqByLkC1xsDPxE1? M3KxVVI2PzR4N{[z
Hep3B  NVzYVppLTnWwY4Tpc44hSXO|YYm= MV[xNEDPxE1? MUm0POKhcMLi M1vmcJJm\HWlZYOgeIhmKGWwaHHuZ4lv\yCnZn\lZ5Qhd2ZiQl3QMVY> MVuyOVY{OzV4NB?=
Hep3B  M2\hZ2Z2dmO2aX;uJGF{e2G7 MV[wMlEuOTBizszN NHv3NHIzPCCq MUnzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? NV7CdHlEOjV4M{O1OlQ>
HEK293 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\MTWlEPTB;Nz6xOOKhyrIEoECuN|bDqM7:TR?= MX:yOVYxOzF{Mh?=
DU145 NWXWXHRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofOTWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP NHjqbFUzPTZyM{GyNi=>
HCT15 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwOEJCpOKyyqByLkCxxsDPxE1? MoXYNlU3ODNzMkK=
T47D NUThVVRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTNwMUlCpOKyyqByLkGxxsDPxE1? Mn76NlU3ODNzMkK=
SMMC-7721 M2\ORmZ2dmO2aX;uJGF{e2G7 Mnu3OFAh|ryP NVny[JIxPDhiaB?= M37YPWROW09? MojybY5lfWOnczFOt2gzSVhiZn;jbUBnd3KvYYTpc44> M3jhNFI2PTR2M{[x
MDA-MB-231 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Ta[|czyqCq M{i1N2lEPTB;MkGuNuKhyrIEoESuNuKh|ryP NGHye3AzPTR6NkKxPS=>
MCF-7 MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnpfmw4OsLiaB?= NF;Wd2NKSzVyPUGwMlnDqMLzwrCyMlHDqM7:TR?= NH2we|kzPTR6NkKxPS=>
Jurkat NHjad41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHMcnI4OsLiaB?= Mm\hTWM2OD1zLkNCpOKyyqBzLkZCpO69VQ>? MkLaNlU1QDZ{MUm=
HeLa MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT5SJQ4OsLiaB?= M{jJemlEPTB;Mz65xsDDucLiMj6zxsDPxE1? M1jRfFI2PDh4MkG5
MCF7  MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke0OU0yODBizszN M{LEUlch\A>? MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWG0eIlOOjV2N{K2NVk>
K562 M1\Ud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUG3NuKhcA>? M1LjRmlEPTB;MD6yPeKh|ryP Mke0NlUzQDJ4NUO=
K/VP.5 M3q4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVniRlBUPzMEoHi= MkLXTWM2OD12LkpCpO69VQ>? NXHO[3lSOjV{OEK2OVM>
SH-EP  MoXvSpVv[3Srb36gRZN{[Xl? Mn7RNlDDqM7:Zz;tcC=> NEW5[mkzPMLiaB?= NWnhVldWcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGWwZH;n[Y5wfXNiRFXQVC=> NH7J[HMzPTJ4MUm4NS=>
SCC25 NVrpN3B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjuNlTDqGh? NHvYb|NKSzVyPUSzMlPDqMLzwrCxMlEzyqEQvF2= MlfENlUzOjB5Mkm=
CAL27 M1jLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\NW|I1yqCq M1\SdmlEPTB;NUKuNeKhyrIEoEGuNFnDqM7:TR?= MWSyOVIzODd{OR?=
FaDu MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuyOOKhcA>? NVrHVFFVUUN3ME2yOU45QcLiwsJCpFEvOTQEoN88US=> MofDNlUzOjB5Mkm=
SCC25 NWDo[lhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nvd|Q5yqCq NWHnbVhRUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> M17aTVI2OjJyN{K5
CAL27 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu0POKhcA>? MUTJR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP MWeyOVIzODd{OR?=
FaDu NWCwOJQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO0POKhcA>? NIDsVnpKSzVyPU[uOFPDqMLzwrCxMlE{yqEQvF2= MV6yOVIzODd{OR?=
SCC25 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInaUZk4OsLiaB?= MnXGTWM2OD16LkSxxsDDucLiMT6xNeKh|ryP NXewW5Q4OjV{MkC3Nlk>
CAL27 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\PcFg4OsLiaB?= MkiyTWM2OD12LkK3xsDDucLiMT6xOOKh|ryP NGXue3AzPTJ{MEeyPS=>
FaDu MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[zdGpCPzMEoHi= NYfZTlNRUUN3ME21MlAzyqEEsdMgNU4yPcLizszN NUfqVVB6OjV{MkC3Nlk>
MCF-7 Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWm0POKhcMLi M1PJfGROW09? M1P3OmlEPTB;Nz6yxsDDucLiMD64xsDPxE1? M3HEZ|I2OjF4M{e4
T-47D Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nidVQ5yqCqwrC= MnzISG1UVw>? MY\JR|UxRTdwN9MgxtHDqDBwN9Mg{txO MoTWNlUzOTZ|N{i=
MDA-MB-231 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7TTm5PPDkEoHlCpC=> MXrEUXNQ NFvPcYtKSzVyPUGyMljDqMLzwrCxMlDDqM7:TR?= NFfOcnQzPTJzNkO3PC=>
DU145 MmG3RZBweHSxc3nzJGF{e2G7 Mnu2NVAuOTByIN88US=> M{X5SlghcA>? M3L4VGROW09? NGPlWXVqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= NX;3cpBzOjVzNEm2PFE>
DU145 stem-like NFTGfVFCeG:ydH;zbZMhSXO|YYm= MYGxNE0yODBizszN MYq4JIg> MWLEUXNQ NHLTW|VqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnGyNlUyPDl4OEG=
DU145 NXLaPVh6TnWwY4Tpc44hSXO|YYm= NVnFd3EyOTBvMUCwJO69VQ>? NVeyOmxsOiCq NYS0WHRlTE2VTx?= M3PqZYlv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mo\iNlUyPDl4OEG=
DU145 stem-like MmXQSpVv[3Srb36gRZN{[Xl? NEjHN2EyOC1zMECg{txO NEf2TnEzKGh? MXfEUXNQ MXHpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4n5fVI2OTR7Nkix
UW228-3 M3TkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XvO|AvODFvM{CwJO69VQ>? NHrzcXc1QCCq MVLEUXNQ MlP6TWM2OD1yLkm5xsDPxE1? NGXCWnEzPTFzOUG4OS=>
NSCs MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLjV5pnOC5yMT2zNFAh|ryP MYK0PEBp MVHEUXNQ NVHIZ3pZUUN3ME2wMlMuO8LizszN MlizNlUyOTlzOEW=
MKL-1  NEDLdIpHfW6ldHnvckBCe3OjeR?= MV[xNE0yODByIH7N NUTmUohqPCCm NH\uOVFqdmS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gUWhENUliZYjwdoV{e2mxbh?= NFzNZ3AzPTFzNke1OC=>
MCF7 EV NHzPXnhHfW6ldHnvckBCe3OjeR?= M2\RTlExNTFyMDFOwG0> NV;tUHY6OuLCiXi= M4\pcIlv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ M33Z[lI2ODh6MkCz
MCF 7BMI1 MXfGeY5kfGmxbjDBd5NigQ>? MlL5NVAuOTByIN88US=> NVz0PVRmOuLCiXi= M37VZYlv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ Mn36NlUxQDh{MEO=
MCF7 EV MYTGeY5kfGmxbjDBd5NigQ>? NILORpcyOC1zMECg{txO NIDrUJAz6oDLaB?= NEXHVYdGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> MVyyOVA5QDJyMx?=
MCF7 BMI1 NGT3So9HfW6ldHnvckBCe3OjeR?= NGPBZY4yOC1zMECg{txO M{\Sc|LjiImq MnfVSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u NELuNpkzPTB6OEKwNy=>
HepG2 M324U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXkSG1UV8Li NVnueXh6UUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> Mke4NlUxPzh|MUG=
MOLT-3 M{\lTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DkNWROW00EoB?= NFXKR41KSzVyPUCuNFUyyqEEsdMgNE4xODMEoN88US=> M3rYcFI2ODd6M{Gx
HT1080 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L5R|EuOTByIN88US=> Ml3kOE8zPC92ODDo NFzTbJNFVVORwrC= NETVVpFqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= Mnj4NlUxPzhyNkS=
HT1080 MoS4SpVv[3Srb36gRZN{[Xl? M{f5UFAvODByMT2xNFAh|ryP M4q4TlEuOjRiaB?= NI[xPVRFVVORwrC= MYDpcoR2[2W|IICtdFU{MHOnckG1LUBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? M2jNWlI2ODd6ME[0
HT1080 NV[yclJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPpNE4xODBzLUGwNEDPxE1? NV;zToFqOjRiaB?= NXnKWYYyTE2VT9Mg MWXjZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| M4\Db|I2ODd6ME[0
HD-MY-Z NVfRU|BRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrvUGEzPC92OD:3NkBp M2[yS2lEPTExvK6xNFAh|ryP MUKyOVA1QDJ|Nh?=
DOHH-2 M1Xqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSyOEBp M2TG[GlEPTExvK6xNFAh|ryP M1;aOFI2ODR6MkO2
DOHH-2 M1LRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVS0PEBp NXntRmt2UUN3ME2xPU46yqEQvF2= NITIW|MzPTB2OEKzOi=>
DOHH-2 NGq4e4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInmd4w4OiCq NF72c|NKSzVyPUZCpO69VQ>? MWSyOVA1QDJ|Nh?=
REH MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXKyOEBp M2\0XGlEPTB;MD6wNlfDqM7:TR?= NGrqO5YzPTB2OEKzOi=>
REH M3LYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXtU4E1QCCq NGTER5RKSzVyPUCuNFE1yqEQvF2= MkHPNlUxPDh{M{[=
REH MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljSO|IhcA>? MlzaTWM2OD1yLkCxOeKh|ryP NV;2NHJTOjVyNEiyN|Y>
HH NYTaVHVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPXNlQhcA>? MXzJR|UxRTFyND63xsDPxE1? NGD0bpczPTB2OEKzOi=>
HH NIrtdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\4VmE1QCCq MWDJR|UxRTR6LkdCpO69VQ>? NFfuTlczPTB2OEKzOi=>
HH M2HTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe3NkBp NGfuSoFKSzVyPUG0MlfDqM7:TR?= NHTI[GEzPTB2OEKzOi=>
HuT-78 NX31[21LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTmcnMzPCCq NUTxT4R3UUN3ME25MlPDqM7:TR?= NGjDeoIzPTB2OEKzOi=>
HuT-78 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm0PEBp MWDJR|UxRTRwM9Mg{txO NGf4[lUzPTB2OEKzOi=>
HuT-78 NFr3[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPmdFM4OiCq Mm\pTWM2OD12LkNCpO69VQ>? Ml;yNlUxPDh{M{[=
OPM-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPXdWJrOjRiaB?= NF;IfpJKSzVyPUK0MlHDqM7:TR?= Ml3KNlUxPDh{M{[=
OPM-2 NWDZR5UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\1bINRPDhiaB?= MYjJR|UxRTUEoN88US=> MmnMNlUxPDh{M{[=
OPM-2 M4fjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknQO|IhcA>? NX[xO4h[UUN3ME2xMlPDqM7:TR?= NUXL[5FlOjVyNEiyN|Y>
RPMI-8226 NGL5[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELzcYIzPCCq MkHOTWM2OD1zME[uOuKh|ryP NEOySJkzPTB2OEKzOi=>
RPMI-8226 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWC0PEBp MmXkTWM2OD17MT6xxsDPxE1? MYCyOVA1QDJ|Nh?=
RPMI-8226 NETFdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ezNVczKGh? MmDpTWM2OD1zND65xsDPxE1? MoT4NlUxPDh{M{[=
U-266 NInmcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVflOHFCOjRiaB?= MVzJR|UxRTh4LkNCpO69VQ>? NHnkcIMzPTB2OEKzOi=>
U-266 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHIWXQ1PDhiaB?= MXnJR|UxRTZ6LkVCpO69VQ>? M{THVVI2ODR6MkO2
U-266 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK5O|IhcA>? NIDaflFKSzVyPUK3MlTDqM7:TR?= MljFNlUxPDh{M{[=
Kelly M1TKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\2TY4xNTFyIN88US=> NFK0VWc4OsLiaB?= MXLJR|UxRTFwNUG4xsDPxE1? NETj[VQzPTByOEmwNC=>
SH-SY5Y  MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu4PVZCOC1zMDFOwG0> NWntcIF5PzMEoHi= NEPX[otKSzVyPUCuO|U1yqEQvF5CpC=> MWOyOVAxQDlyMB?=
SK-N-AS NF7wenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPTNE0yOCEQvF2= NVzHXGFHPzMEoHi= MX\JR|UxRTFwN{GyxsDPxE4EoB?= MYiyOVAxQDlyMB?=
SK-N-DZ MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke4NE0yOCEQvF2= M{\6SlczyqCq M3;hdmlEPTB;NT60PFXDqM7:TR?= MWKyOVAxQDlyMB?=
HepG2 NVHYOIQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fTNFQ5yqCq NFHKT5JFVVORwrC= MWPJR|UxRTF|Lk[1xsDDucLiMD65NuKh|ryP Mn3NNlQ6QTZzM{[=
A549 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\DRXo1QMLiaB?= NGjrfXFFVVORwrC= NGj5dHZKSzVyPUK0NU46yqEEsdMgN|EvOjQEoN88US=> MU[yOFk6PjF|Nh?=
MCF7 NUHYXm5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjUOFjDqGh? MXTEUXNQyqB? M{n4VWlEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN MlHWNlQ6QTZzM{[=
HL-60  M4fnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf3eW84OsLiaB?= NFrRTpdKSzVyPUCuNVLjiIYQvF2= NYTndpZMOjR7OUOwNVQ>
HL-60[R] NIHLfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Phb|czyqCq MmH2TWM2OD1|LkGy5qCG|ryP NF3MTFUzPDl7M{CxOC=>
MIAPACA NWDWXFgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv5OHRNT0l3ME2xMlMhyrFiMD6wN{DPxE1? NFXG[mozPDl3M{iyNS=>
MCF-7 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnoSlVIUTVyPUCuNlUhyrFiMD6xJO69VQ>? MoDlNlQ6PTN6MkG=
HeLa M3vQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGwWVc5T0l3ME2wMlY1KMLzIECuOEDPxE1? MWSyOFk2Ozh{MR?=
MO59K  M1ixfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe3JIQ> MWLJR|UxRTBwMUhihKXPxE1? NFXBW|IzPDl3M{W2NS=>
MO59J M176fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO1O{Bl NH;xWG1KSzVyPUCuNgKBjc7:TR?= NHyyTHMzPDl3M{W2NS=>
ME 180 NU\YPYxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DlcVQ5yqCqwrC= M1HrPGlEPTB;OD65xsDDucLiMD6z5qCG|ryP NWnX[pFvOjR7NUOwNlc>
MCF-7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz6Xmg1QMLiaNMg MmD1TWM2OD1{Mz65JOKyKDBwM,MAie69VQ>? MVmyOFk2OzB{Nx?=
HeLa MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjvOFjDqGkEoB?= M3vOOGlEPTB;ND63NUDDuSBzLkVihKXPxE1? Mn3BNlQ6PTNyMke=
MDA-MB-453 Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX60POKhcMLi NH35NGlKSzVyPUGyMlUhyrFiMD64OgKBjc7:TR?= NWD0OmIyOjR7NUOwNlc>
MDA-MB-231 MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT2[241QMLiaNMg NVzDbnN5UUN3ME2yOE4zOiEEsTCyMlk16oDHzszN M{PKZVI1QTV|MEK3
PC-3 NGiyeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTWSpBUPDkEoHlCpC=> NUX6O4poUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= MkLtNlQ6PTNyMke=
HT-29 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK0POKhcMLi M1XrXGlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= MV6yOFk2OzB{Nx?=
BGC-823 NUHjeHhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[3blQ5yqCqwrC= MlP6TWM2OD12Mz63OEDDuSB3LkGz5qCG|ryP NULqb3BDOjR5OUO4O|c>
HeLa MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHI[Wc1QMLiaNMg M4OzN2lEPTB;MkC5MlkxKMLzIEGzMlQzKOLChd88US=> NG\ZdYYzPDd7M{i3Oy=>
A549 NEj1dWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTtOFjDqGkEoB?= MnPPTWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= MlKzNlQ4QTN6N{e=
HK-2 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\OXJF7PDkEoHlCpC=> NFHFSItKSzVyPUmuNVchyrFiMT61PQKBjc7:TR?= M3;QeFI1Pzl|OEe3

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[5]
+ 展開

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
細胞試験: [5]
+ 展開
  • 細胞株: Human glioma cell lines CL5
  • 濃度: 80 μg/mL
  • 反応時間: 1 hour
  • 実験の流れ: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Murine angiosarcoma xenografts ISOS-1
  • 製剤: Saline
  • 投薬量: 10 mg/kg
  • 投与方法: i.p. every day for 5 days from day 7
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
5% DMSO+30% PEG 300+H2O
混合させたのち直ちに使用することを推奨します。
15mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 588.56
化学式

C29H32O13

CAS No. 33419-42-0
保管
別名 VP-16, VP-16213

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomeraseシグナル伝達経路

相関Topoisomerase製品

Tags: Etoposideを買う | Etoposide ic50 | Etoposide供給者 | Etoposideを購入する | Etoposide費用 | Etoposide生産者 | オーダーEtoposide | Etoposide化学構造 | Etoposide分子量 | Etoposide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID